David Lieberman MDProfessor of Medicine; Chief, Division of Gastroenterology and Hepatology, Oregon Health and Science University (OHSU), Portland, Oregon
David Lieberman, MD, is Professor of Medicine and was Chief of the Division of Gastroenterology and Hepatology at Oregon Health and Science University (1997-2021) in Portland, Oregon, and the Portland VA Medical Center. Dr. Lieberman is internationally recognized as an expert on colon cancer screening. He is Chairman for VA Cooperative Study # 380, which utilized colonoscopy to screen asymptomatic subjects for colorectal cancer with publications in New England Journal of Medicine, JAMA, Annals of Internal Medicine and Gastroenterology. Dr. Lieberman was the Chairman of the Multi-Society Task Force on Colorectal Cancer (2006-2012), and authored colon cancer screening recommendations in 2008 (CA and Gastroenterology) as well as colonoscopy quality indicators in 2007, review of colorectal cancer screening (JAMA 2016), and recommendations for polyp surveillance (2012 and 2020).
He was the Director of the Clinical Outcomes Research Initiative (CORI), supported by NIH 1999-2016. The project created a national endoscopic data repository for research, with more than 90 peer-reviewed publications to date. Dr. Lieberman served as a member of the National Commission on Digestive Diseases from 2006-2008, President of the American Society for Gastrointestinal Endoscopy (ASGE) in 2001-2002, and Associate Editor of Gastroenterology (2011-2013). He was President of the AGA Institute (2018-2019) and AGA (2019-2020), and Chair of the AGA Colorectal Cancer Task Force (2021-present). He has been an advisor to the President’s Cancer Panel (2020-2021).
Recent Contributions to PracticeUpdate:
- Association of Serrated Polyp Detection Rates With Post-Colonoscopy Colorectal Cancer
- Risk-Adapted Starting Age for Personalized Colorectal Cancer Screening
- Fecal Microbial DNA Markers Serve for Screening Colorectal Neoplasm in Asymptomatic Individuals
- Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection
- Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors
- Germline Genetic Features of Young Patients With Colorectal Cancer
- Modifiable Risk Factors for Sessile Serrated Polyps, Conventional Adenomas, and Hyperplastic Polyps
- Correlation of Distal Polyps With Proximal Advanced Serrated Lesions
- Incidence of Colonic Neoplasia in Patients With Serrated Polyposis Syndrome Who Undergo Annual Endoscopic Surveillance